

PRESS RELEASE

Ziwig launches GYN-ARN, a pioneering study to develop a salivary multi-pathology diagnostic test in gynaecology

Lyon, December 18th, 2023 — Ziwig, the cutting-edge French biotech specialized in the advanced analysis of salivary RNA, announces the launch of GYN-ARN, a highly promising new study in women's health.

This ambitious study follows the success of the studies that led to the development of Ziwig Endotest®, the very first and, to date, only saliva-based diagnostic test for endometriosis. Ziwig Endotest® marks a major step-forward to putting an end to the often long and painful diagnostic odyssey experienced by patients. It is also a significant breakthrough for towards a relevant and efficient care path. <u>To learn more, click here.</u>

Innovation at the service of Women's Health.

The GYN-ARN study aims to identify specific RNA signatures for each of the main gynecological pathologies, whether symptomatic, benign, or malignant, that may require surgery.

This large-scale, 34-month study will involve 2,200 patients from 50 gynecology and oncology centers in 10 countries across Europe, North Africa, and the Middle East. The studied pathologies include endometriosis, adenomyosis, ovarian cysts, fibroids, early cervical dysplasia, as well as uterine and cervical cancers.

The results from GYN-ARN will serve Ziwig's core objective: to develop a reliable, simple, and easily accessible multi-pathology saliva-based test. This next-generation test would be able to provide a diagnosis on these various pathologies and predict a patients' responses to treatment.

Knowing more to treat better

Through its cutting-edge technological platform, Ziwig enhances the understanding of each individual's molecular uniqueness. This new characterization rapidly dispels diagnostic and prognostic uncertainties, empowering patients to be more involved in their healthcare journeys. For healthcare professionals, it strengthens the path toward highly personalized and more relevant medicine. It also contributes to the efficiency of healthcare systems.

About Ziwig

Ziwig® is an innovative French biotech specialized in salivary RNA analysis and Artificial Intelligence. It operates as an ecosystem at the crossroads of several medical, scientific and digital disciplines. Ziwig® is strongly committed to disruptive innovations that support the transformation of healthcare systems towards more effective, more humane and more accessible precision medicine.

PRESS CONTACT Aurélia Adloff - Finn Partners, mobile phone : +33 6 89 38 94 70 sante@finnpartners.com